Chimeric (ASX:CHM) strengthens cancer fight with latest advances to clinical programs

Chimeric Therapeutics (ASX:CHM) aims to become a worldwide leader in the cell therapy sector. The company believes that novel cell therapies hold the potential to treat cancer. In this video, we discuss with Jennifer Chow, the Chief Executive Officer and Managing Director of Chimeric, about the company and its plans. 



The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and